Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Phramongkutklao College of Medicine and Hospital
Glucocorticoids (GCs) remains the mainstay of treatment in SLE. Prolong used of glucocorticoid can be leading to various organ damage, even in low dose (\< 7.5 mg/day). The rational of tapering GCs in SLE who achieve remission or low disease activity is still debated. Recent trial showed the abrupt discontinuation of GCs in sustained clinical remission of SLE increased rate of flare. This study aims compare the flare rate of maintenance versus gradual withdrawal of 5 mg/day prednisone over 24 weeks in systemic lupus erythematosus (SLE) patients with clinically quiescent disease.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged; 20 years
Diagnosis of SLE according to Systemic Lupus International Collaborating Clinic (SLICC) classification SLE criteria, 2012.
Achieved clinically quiescent SLE defined as cSLEDAI-2K = 0 for at least 6 months.
Current treatment regimen including prednisolone 5mg/day. Prednisolone, antimalarials and/or immunosuppressive therapy had to be stable for at least 4 weeks before randomization.
You may not be if
Pregnant or pregnancy planning
Unable to follow the schedules
Overlap with other autoimmune disease, except secondary SjS and APS
Co-morbid with any other condition which required prednisolone treatment
